Inhibition Of mTOR Modulates SLPI Expression: A Potential Role In Kidney Transplant Patients

AMBROSI NELLA; DOTTA A; GUERRIERI DIEGO; CARO FIORELLA; LEON L; SANCHEZ F; BARBIERI M; MENDIBERRI JOSEFINA; RIAL MC; INCARDONA CLAUDIO; CHULUYAN EDUARDO; CASADEI DOMINGO

Philadelphia

Congreso; American Transplant Congress 2015; 2015

Secretory leukocyte protease inhibitor (SLPI) is a serine protease inhibitor secreted by inflammatory and epithelial cells. It functions as an endogenous immunomodulatory, with antiinflammatory and antimicrobial activity, and enhances wound healing.The aim of the present work was to study the effect of mTOR inhibition on the expression of SLPI in vitro and in kidney transplanted patients treated with rapamycin.Peripheral blood mononuclear cells (PBMC) derived from healthy donors (HD) were in vitro treated with PHA or a lysate of M. tuberculosis (Mtb) in the presence of rapamycin. After 24 h of culture, cell supernatants were harvested, and SLPI and cytokines were measured by ELISA and bead array assay. The plasma levels of SLPI and cytokines were measured in kidney transplanted patients, during the first year of the transplant treated with antithymocyte globulin, and an immunosuppressive maintenance therapy consisted of prednisone + MMF + rapamycin or prednisone + MMF + calcineurin inhibitor (CIN).The inhibition of mTOR significantly increased the production of SLPI if the cells were previously treated with PHA or Mtb (p